Quick answers
- What is Dipyridamole used for?
- The FDA-approved label (Dipyridamole, Hikma Pharmaceuticals USA Inc., May 20, 2026) says: “Dipyridamole Injection is indicated as an alternative to exercise in thallium myocardial perfusion imaging for the evaluation of coronary artery disease in patients who cannot exercise adequately. …” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- Does Dipyridamole have a boxed warning?
- No. None of the 8 FDA labels we found for this medicine has a boxed warning.
- Is there a shortage of Dipyridamole?
- No current shortage is listed by the FDA for the products of this medicine (FDA data from October 30, 2026).
- Has Dipyridamole been recalled?
- No recall linked to the products of this medicine appears in the FDA enforcement reports we use.
- Who makes Dipyridamole?
- 8 companies list prescription products of Dipyridamole in the FDA NDC Directory, including Amneal Pharmaceuticals of New York LLC, Oxford Pharmaceuticals, LLC and Zydus Pharmaceuticals USA Inc..
What Dipyridamole is used for
Quoted from the “Indications and Usage” section of the FDA-approved label.
Dipyridamole Injection is indicated as an alternative to exercise in thallium myocardial perfusion imaging for the evaluation of coronary artery disease in patients who cannot exercise adequately. …
— FDA label: Dipyridamole, Hikma Pharmaceuticals USA Inc., effective May 20, 2026. Read the full label on DailyMed →
The FDA has 8 labels for products of this medicine (different makers and forms); uses can differ between them. Check the label that comes with your own medicine.
This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Conditions named on the label
These condition names appear word for word in the label’s “Indications and Usage” text (matched with a reviewed table). Each page lists hospitals whose own websites name the condition.
Related medical specialties
Boxed warning
A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.
The label quoted above has no boxed warning.
0 of 8 FDA labels for this medicine have a boxed warning.
Forms and how it is given
| Dosage forms | Tablet, film coated · Tablet · Injection |
|---|---|
| Route | Oral · Intravenous |
| Prescription products | 16 in the FDA NDC Directory |
What pharmacies pay (NADAC)
The National Average Drug Acquisition Cost (NADAC) is the average price U.S. retail pharmacies paid to buy one unit of a medicine (one tablet, one mL or one gram), from a monthly survey of pharmacy invoices by the Centers for Medicare & Medicaid Services (CMS). State Medicaid programs use it to pay pharmacies.
This is not the price you pay. What you pay depends on your insurance (copay or coinsurance), your pharmacy and any discounts, and pharmacies also charge for filling a prescription. Ask your pharmacist or your health plan what your price will be.
| Strength and form | Generic or brand | Pharmacies pay |
|---|---|---|
| dipyridamole 25 mg tablet | Generic | $0.1307 per tablet |
| dipyridamole 25 mg tablet, film coated | Generic | $0.1307 per tablet |
| dipyridamole 50 mg tablet | Generic | $0.3225 per tablet |
| dipyridamole 50 mg tablet, film coated | Generic | $0.3225 per tablet |
| dipyridamole 75 mg tablet | Generic | $0.2854 per tablet |
| dipyridamole 75 mg tablet, film coated | Generic | $0.2854 per tablet |
NADAC list of November 4, 2026; these prices took effect on October 21, 2026. Shown only where a package’s NDC code matches the NADAC list exactly, and only for that exact strength and form: nothing is averaged across strengths. Strengths and forms not listed here have no NADAC price.
Source: NADAC (National Average Drug Acquisition Cost) 2026, data.medicaid.gov (CMS) →
Companies that list this medicine
Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.
- Amneal Pharmaceuticals of New York LLC3 products
- Oxford Pharmaceuticals, LLC3 products
- Zydus Pharmaceuticals USA Inc.3 products
- Zydus Lifesciences Limited3 products
- Remedyrepack Inc.1 product
- Henry Schein, Inc.1 product
- HF Acquisition Co LLC, DBA HealthFirst1 product
- Hikma Pharmaceuticals USA Inc.1 product
FDA approval history
- ANDA: Abbreviated New Drug Application: how a generic version is approved.
Generic approvals (4)
- ANDA074521Hikma · October 18, 1996
- ANDA040542Oxford Pharms · April 21, 2006
- ANDA040782Impax Labs · July 18, 2007
- ANDA040874Zydus Pharms USA Inc · January 28, 2008
Shortage status
The FDA drug shortage list does not show these products.
Recalls
No recall linked to these products (by their NDC code) appears in the FDA enforcement reports.
Official identifiers
| RxCUI (RxNorm) | 197622, 309952, 309953, 309955 |
|---|---|
| SPL set ID of the quoted label | 6093dcd9-82d2-414f-8507-eda22c14f626 |
| FDA labels (SPL) | 8 |
| FDA applications | 4 ANDA |
| Active ingredients (FDA) | DIPYRIDAMOLE |
Sources
- FDA-approved label on DailyMed (National Library of Medicine) — Dipyridamole, Hikma Pharmaceuticals USA Inc., effective May 20, 2026; via openFDA, FDA data exported October 30, 2026, retrieved October 31, 2026
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
- Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →